A Phase 1 Trial of Menin-inhibitor Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory KMT2A-r/NUP98-r/NPM1-m Acute Leukemia

Inclusion Criteria: * Age: 0-21 years (and at least 5 kg body weight), with a minimum of 80% of participants under 18 years of age. * Diagnosis: KMT2A-r, NPM1-m, or NUP98-r acute leukemia in first or greater relapse or refractory to standard (re-) induction treatment (including HSCT). Please note that genetic alteration must be confirmed by the central laboratory, or the participant will discontinue protocol therapy. * Eligible participants also must fulfill one of the following conditions: 1. Bone marrow relapse is defined as: 1. A single bone marrow sample showing ≥ 5% leukemic bla…